March 27, 2015
Authored and Edited by Morgan E. Smith
The Eastern District of Virginia recently opined on the issue of standing to sue under Sections 14(3) and 43(a) of the Lanham Act and reversed the TTAB’s decision cancelling Belmora’s FLANAX mark. Belmora began using its FLANAX mark in the United States for pain relievers in 2004 and obtained a federal registration in 2005. Bayer had sold similar pain relievers in Mexico under its Mexican-registered FLANAX mark since the 1970s, but had not used the FLANAX mark in the United States. Bayer successfully petitioned to cancel Belmora’s FLANAX registration in April 2014 pursuant to Section 14(3) of the Lanham Act, which prohibits misrepresentation as to source. Bayer then brought suit against Belmora under Section 43(a), which was consolidated with Belmora’s appeal of the TTAB decision.
The court found that Bayer lacked standing to sue under Section 43(a)(1)(A) of the Lanham Act because its interests did not fall within the “zone of interests” Congress intended to protect. While Section 43(a)(1)(A) was designed to protect “qualifying” unregistered marks, even the unregistered mark must be used in commerce in the United States in order to establish standing. Because Bayer had not used its FLANAX mark in United States commerce, it lacked standing to sue for false designation of origin. Alternatively, Bayer’s claim failed because it failed to plead facts showing that Belmora’s acts proximately caused it economic or reputational injury. Without a showing of injury to reputation or sales, Bayer’s Section 43(a)(1)(B) claim also failed.
Using similar logic, the court concluded Bayer also lacked standing under Section 14(3). Even though Section 14(3) does not contain a use requirement on its face, the court determined that, consistent with case law and other Lanham Act provisions like Section 43(a), Section 14(3) requires use of the mark in the United States in order to establish standing.
Bayer also could not petition to cancel Belmora’s FLANAX mark under Article 6bis of the Paris Convention. Article 6bis grants certain protections for “well-known” or “famous” marks that have not been adopted in the United States. Because the Paris Convention is not self-executing and Sections 44(b) and (h) of the Lanham Act do not incorporate Article 6bis into U.S. law, an independent cause of action under Article 6bis does not exist.
Belmora LLC v. Bayer Consumer Care, trademark cancellation, Paris Convention, Section 43(a), Trademark Trial and Appeal Board (TTAB)
Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.